Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
…, M Domine, P Clingan, MJ Hochmair… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer …
…, K Hotta, D Trukhin, G Statsenko, MJ Hochmair… - The Lancet …, 2021 - thelancet.com
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide)
showed a significant improvement in overall survival versus platinum–…
showed a significant improvement in overall survival versus platinum–…
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled …
…, K Hotta, D Trukhin, G Statsenko, MJ Hochmair… - The Lancet, 2019 - thelancet.com
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial
…, HL West, HJM Groen, MJ Hochmair… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)–rearranged
non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease …
non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease …
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell …
…, E Felip, M Dómine, R Hui, MJ Hochmair… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly
improved overall survival (OS) and progression-free survival (PFS) compared with …
improved overall survival (OS) and progression-free survival (PFS) compared with …
[HTML][HTML] Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
…, JY Han, JS Lee, MJ Hochmair… - … England Journal of …, 2018 - Mass Medical Soc
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
[HTML][HTML] Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
…, J Vansteenkiste, M Hochmair… - … England Journal of …, 2020 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …
[HTML][HTML] First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
…, L Havel, M Krzakowski, MJ Hochmair… - … England Journal of …, 2018 - Mass Medical Soc
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …
[HTML][HTML] Perioperative durvalumab for resectable non–small-cell lung cancer
…, JM Taube, G Galffy, M Hochmair… - … England Journal of …, 2023 - Mass Medical Soc
Background Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients
with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine …
with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine …
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
…, H Horinouchi, W Mao, M Hochmair… - … England Journal of …, 2024 - Mass Medical Soc
Background Platinum-based chemotherapy is the recommended adjuvant treatment for patients
with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy …
with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy …